查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606847

子宮內膜癌治療市場：按治療方法、等級和最終用戶分類 - 全球預測 2025-2030

Endometrial Cancer Treatment Market by Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), Grade (Type I, Type II), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年子宮內膜癌治療市場規模為84.2億美元，預計2024年將達到88.7億美元，複合年成長率為5.47%，2030年將達到122.3億美元，預計將達到1000萬美元。

隨著發病率的增加、醫療技術的進步以及對該疾病的進一步了解，子宮內膜癌治療市場不斷發展。子宮內膜癌主要影響子宮內膜，是最常見的婦科惡性之一。人口老化和肥胖率上升強調了對有效治療方法的需求。治療包括手術介入、放射線治療、荷爾蒙療法和化療，目的是提高存活率和患者的生活品質。最終使用者包括專注於創新治療方法的醫院、診所和研究機構。市場成長受到個人化醫療、免疫療法的進步和癌症研究資金增加的影響。開發標靶治療和非侵入性診斷工具存在機會，可以顯著改善早期檢測和治療結果。此外，製藥公司與研究機構之間的合作可以加快技術創新的步伐。然而，它受到治療成本高、潛在副作用和嚴格監管要求等限制的挑戰。此外，全球在獲得醫療保健方面的差異可能會限制市場成長。儘管存在這些挑戰，市場仍為生物標記研究的創新提供了巨大的機會，從而提高了診斷和治療計劃的準確性。市場競爭激烈，大型製藥企業和新興生技公司都專注於研發投資。主要建議包括利用夥伴關係關係進行研究合作、投資新技術平台進行研究和開發，以及解決成本效益問題以改善患者的可近性。先進的基因組和分子分析方面的創新可能會塑造子宮內膜癌治療的未來，並有可能引入突破性的治療方法，重新定義患者的治療結果和醫療保健服務。

主要市場統計
基準年[2023] 84.2億美元
預計年份 [2024] 88.7億美元
預測年份 [2030] 122.3億美元
複合年成長率（%） 5.47%

市場動態：快速發展的子宮內膜癌治療市場的關鍵市場洞察

子宮內膜癌治療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 1 型和 2 型子宮內膜癌的全球盛行率
    • 政府努力擴大子宮內膜癌治療的採用
    • 個人化和標靶化子宮內膜癌治療的出現
  • 市場限制因素
    • 子宮內膜治療的報銷結構有限
  • 市場機會
    • 持續研究開發新型子宮內膜癌治療方法
    • 子宮內膜癌藥物獲得政府有利核准
  • 市場挑戰
    • 與特定治療相關的監管障礙和風險

波特五力：駕馭子宮內膜癌治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解子宮內膜癌治療市場的外部影響

外部宏觀環境因素在塑造子宮內膜癌治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解子宮內膜癌治療市場的競爭狀況

對子宮內膜癌治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣子宮內膜癌治療市場供應商的績效評估

FPNV定位矩陣是評估子宮內膜癌治療市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製子宮內膜癌治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對子宮內膜癌治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球 1 型和 2 型子宮內膜癌的盛行率
      • 政府努力擴大子宮內膜癌治療的採用
      • 個人化和標靶化子宮癌治療的出現
    • 抑制因素
      • 子宮內膜治療的報銷結構有限
    • 機會
      • 正在進行的研究活動旨在開發子宮內膜癌的新治療方法
      • 子宮內膜癌藥物獲得政府有利核准
    • 任務
      • 與某些治療相關的監管障礙和風險
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療區分的子宮內膜癌治療市場

  • 化療
  • 免疫療法
  • 放射治療

第7章子宮內膜癌治療市場：依等級

  • Ⅰ型
  • II型

第8章子宮內膜癌治療市場：依最終用戶分類

  • 門診手術中心
  • 癌症中心
  • 醫院/診所

第9章北美及南美子宮內膜癌治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區子宮內膜癌治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲子宮內膜癌治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Context Therapeutics Inc.
  • CooperSurgical Inc.
  • Eisai Co., Ltd.
  • Elekta AB
  • F. Hoffmann-La Roche AG
  • General Electric Company
  • GlaxoSmithKline PLC
  • Hologic Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Koninklijke Philips NV
  • LiNA Medical ApS
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-521BAA36EC26

The Endometrial Cancer Treatment Market was valued at USD 8.42 billion in 2023, expected to reach USD 8.87 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 12.23 billion by 2030.

The market for endometrial cancer treatment continues to evolve in response to increasing incidence rates, advancements in medical technology, and a deeper understanding of the disease. Endometrial cancer primarily affects the lining of the uterus and is one of the most common gynecological malignancies. The necessity for effective treatments is underscored by a growing aging population and rising obesity rates, both of which contribute to higher susceptibility. Treatment encompasses surgical interventions, radiation, hormone therapies, and chemotherapy, targeted towards improving survival rates and patients' quality of life. The end-users include hospitals, clinics, and research institutions focusing on innovative therapeutic approaches. Market growth is influenced by ongoing advancements in personalized medicine and immunotherapy, as well as increased funding for cancer research. Opportunities lie in the development of targeted therapies and non-invasive diagnostic tools, which can significantly boost early detection and treatment outcomes. Moreover, collaborations between pharmaceutical companies and research institutions can accelerate the pace of innovation. However, limitations such as high treatment costs, potential side effects, and stringent regulatory requirements pose challenges. Furthermore, disparities in healthcare access globally can restrict market growth. Despite these challenges, the market offers robust opportunities for innovation in biomarker research, enhancing the precision of diagnosis and treatment plans. The nature of the market is highly competitive, driven by major pharmaceutical companies and emerging biotech firms focusing on R&D investments. Key recommendations include leveraging partnerships for research collaborations, investing in new technology platforms for drug development, and addressing cost-effectiveness to improve patient access. Innovations in advanced genomic and molecular profiling will likely shape the future of endometrial cancer treatment, offering the potential to introduce groundbreaking therapies that can redefine patient outcomes and healthcare delivery.

KEY MARKET STATISTICS
Base Year [2023] USD 8.42 billion
Estimated Year [2024] USD 8.87 billion
Forecast Year [2030] USD 12.23 billion
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endometrial Cancer Treatment Market

The Endometrial Cancer Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevelance of type 1 and type 2 endometrial cancer worldwide
    • Government initiatives to expand endometrial cancer treatment adoption
    • Emergence of personalized and targeted uterine cancer therapy
  • Market Restraints
    • Limited reimbursement structure for endometrial treatment
  • Market Opportunities
    • Ongoing research activities to develop novel endometrial cancer treatments
    • Favorable government approvals for endometrial cancer drugs
  • Market Challenges
    • Regulatory hurdles and risk associated with certain treatment

Porter's Five Forces: A Strategic Tool for Navigating the Endometrial Cancer Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endometrial Cancer Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endometrial Cancer Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endometrial Cancer Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endometrial Cancer Treatment Market

A detailed market share analysis in the Endometrial Cancer Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endometrial Cancer Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endometrial Cancer Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endometrial Cancer Treatment Market

A strategic analysis of the Endometrial Cancer Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endometrial Cancer Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca PLC, Bayer AG, Becton, Dickinson and Company, Boston Scientific Corporation, Bristol-Myers Squibb Company, Celgene Corporation, Context Therapeutics Inc., CooperSurgical Inc., Eisai Co., Ltd., Elekta AB, F. Hoffmann-La Roche AG, General Electric Company, GlaxoSmithKline PLC, Hologic Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Koninklijke Philips N.V., LiNA Medical ApS, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Siemens Healthineers AG, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Endometrial Cancer Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Chemotherapy, Immunotherapy, and Radiation Therapy.
  • Based on Grade, market is studied across Type I and Type II.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevelance of type 1 and type 2 endometrial cancer worldwide
      • 5.1.1.2. Government initiatives to expand endometrial cancer treatment adoption
      • 5.1.1.3. Emergence of personalized and targeted uterine cancer therapy
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement structure for endometrial treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research activities to develop novel endometrial cancer treatments
      • 5.1.3.2. Favorable government approvals for endometrial cancer drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and risk associated with certain treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Endometrial Cancer Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. Chemotherapy
  • 6.3. Immunotherapy
  • 6.4. Radiation Therapy

7. Endometrial Cancer Treatment Market, by Grade

  • 7.1. Introduction
  • 7.2. Type I
  • 7.3. Type II

8. Endometrial Cancer Treatment Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Cancer Centers
  • 8.4. Hospitals & Clinics

9. Americas Endometrial Cancer Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Endometrial Cancer Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Endometrial Cancer Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Becton, Dickinson and Company
  • 5. Boston Scientific Corporation
  • 6. Bristol-Myers Squibb Company
  • 7. Celgene Corporation
  • 8. Context Therapeutics Inc.
  • 9. CooperSurgical Inc.
  • 10. Eisai Co., Ltd.
  • 11. Elekta AB
  • 12. F. Hoffmann-La Roche AG
  • 13. General Electric Company
  • 14. GlaxoSmithKline PLC
  • 15. Hologic Inc.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Karyopharm Therapeutics Inc.
  • 18. Koninklijke Philips N.V.
  • 19. LiNA Medical ApS
  • 20. Merck & Co., Inc.
  • 21. Novartis AG
  • 22. Pfizer Inc.
  • 23. Sanofi S.A.
  • 24. Siemens Healthineers AG
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. ENDOMETRIAL CANCER TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENDOMETRIAL CANCER TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOMETRIAL CANCER TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TYPE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY CANCER CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY GRADE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ENDOMETRIAL CANCER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. ENDOMETRIAL CANCER TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 146. ENDOMETRIAL CANCER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023